Express Pharma

Lupin receives approval for generic Livalo tablets

3

The tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol

Lupin has received tentative approval for its Pitavastatin tablets, 1 mg, 2 mg, and 4 mg from the US Food and Drug Administration (US FDA) to market a generic version of Kowa’s Livalo tablets 1 mg, 2 mg, and 4 mg. The filing is from Lupin’s Pithampur (Indore) manufacturing facility.

Pitavastatin Tablets, 1 mg, 2 mg and 4 mg are the AB rated generic equivalent of Kowa’s Livalo Tablets, 1 mg, 2 mg and 4 mg. Pitavastatin Tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.

 

Comments are closed.